Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)

A Parallel, Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Efficacy and Safety of MT10109L Versus BOTOX® in Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)

This study design is multi-center, randomized, double-blind, parallel group, active controlled, phase 3 clinical trial(Including randomized, double-blind, parallel group, active controlled, preliminary study). Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will be intramuscularly injected with the study drug or the comparator at a total of 20U(4U/0.1ml each)in five sites of the glabella line. Thereafter, follow-up visits will be made 4 weeks, 10weeks, 16weeks and efficacy and safety assessments will be conducted for total 16 weeks.

Study Overview

• Status: Completed
• Conditions: Glabella Line Severity
• Intervention / Treatment: Drug: Botulinum Toxin Type A

• Study Type: Interventional
• Enrollment (Actual): 168
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Korea, Republic of
  • Dongdaemun-gu
    • Seoul, Dongdaemun-gu, Korea, Republic of
      • The Catholic University of Korea, ST. Paul's Hospital
  • Jung-gu
    • Incheon, Jung-gu, Korea, Republic of
      • Inha University Hospital
  • Kangdong-gu
    • Seoul, Kangdong-gu, Korea, Republic of
      • Kyung Hee University Hospital at Gangdong

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Main inclusion criteria

  1. Patients attaining ≥grade 2(moderate) in the investigator's rating of the severity of glabella line at maximum frown

• Other inclusion criteria

  1. Men and women aged between 20 and 65
  2. Patients who him/herself or him/her legal representatives voluntarily signed the informed consent
  3. Patients who can comply with the study procedures and visit schedule

Exclusion Criteria:

1. Patients with general neuromuscular synaptic disorder(e.g. Myasthenia gravis, Lambert-Eaton syndrome, Amyotrophic lateral sclerosis)
2. Patients who have bleeding tendency or taking anti-coagulant
3. Patients suffering from acute diseases
4. Patients who have been injected with botulinum toxin within past 3 months before the injection
5. Patients with allergy or hypersensitivity to the investigational products or their components

6. Patients who are pregnant or lactating or found pregnancy through the urine or serum test or disagreed to avoid pregnancy during 16 weeks study period

   * All childbearing female subjects, excepting who had amenorrhea over 12 months or sterilization operation(bilateral tubal ligation, bilateral oophorrectomy or hysterectomy), shouldn't be enrolled the study until they tested negative on pregnancy test(urine or serum). The contraceptions which are medically allowable are spermicides, oral contraceptives, barrier method, intrauterine contrace, complete sexual abstinence

7. Patients who have been given any of the following drugs within previous 4 weeks at screening

   • ① Muscle relaxants: Tubocurarine Chloride, Dantrolene Sodium, baclofen etc.
   • ② Spectinomycin HCl
   • ③ Aminoglycoside antibiotics: gentamicin sulfate, neomycin sulfate etc.
   • ④ Polypeptide antibiotics: Polymyxin B Sulfate etc.
   • ⑤ Tetracycline antibiotics
   • ⑥ Lincomycin (lincosamides)
   • ⑦ Anticholinergic drugs: butylbromide bromide, Trihexyphenidyl HCl etc.
   • ⑧ Benzodiazepines and similar drugs: Diazepam, Etizolam etc.
   • ⑨ Benzamide drugs: Tiapride HCl, Sulpiride etc.
8. Patients with the history of facial nerve paralysis or the symptoms of eyelid ptosis
9. Patients with skin damage or infection at the injection site.

10. Patients who have received or have a plan to receive other procedures which may affect glabella and forehead lines within 6 months

    * These treatments include soft tissue augmentation in the range of glabella (e.g. hyaluronic acid or collagen-type implants), medium depth peels, facial lifting, dermal photorejuvenation et cetera.

11. Patients whose glabella lines cannot be satisfactorily improved with physical method since the lines are not flattened even using hands
12. Patients who are participating in other clinical trials or have participated in other clinical trials within 30days of the screening date.
13. Patients who are unable to communicate or follow the instructions
14. Patients who are not eligible for this study at the discretion of the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: MT10109L(Botulinum toxin type A)	Drug: Botulinum Toxin Type A; 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
ACTIVE_COMPARATOR: BOTOX® 50U(Botulinum toxin type A)	Drug: Botulinum Toxin Type A; 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Investigator's live assessment of glabella line improvement rate	Glabella line improvement rate determined by investigator's live assessment of glabella line severity at maximum frown	4 weeks after the injection

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Investigator's live assessment of glabella line improvement rate	Glabella line improvement rate determined by investigator's live assessment of glabella line severity at maximum frown	16 weeks after the injection
Investigator's live assessment of glabella line improvement rate	Glabella line improvement rate determined by investigator's live assessment of glabella line severity at rest.	4, 16 weeks after the injection
Investigator's photographic assessment of glabella line improvement rate	Glabella line improvement rate determined by investigator's photographic assessment of glabella line severity at maximum frown	4 weeks after the injection
Investigator's photographic assessment of glabella line improvement rate	Glabella line improvement rate determined by investigator's photographic assessment of glabella line severity at rest.	4 weeks after the injection
Subject's assessment of glabella line improvement rate	Glabella line improvement rate determined by subject's assessment of glabella line severity.	4, 10, 16 weeks after the injection
Subject's satisfaction questionnaire	Subject's satisfaction of glabella line improvement at 4, 10, 16 weeks after the injection.	4, 10, 16 weeks after the injection
Number of adverse events in subjects	Number of adverse events occuring in all subject for the entire study period.	Up to 16 weeks

Collaborators and Investigators

• Sponsor: Medy-Tox
• Investigators: Principal Investigator: Hoon Kang, M.D., Catholic University of Korea Saint Paul's Hospital; Principal Investigator: Gwang Seong Choi, M.D., Ph.D., Inha University Hospital; Principal Investigator: Woo Young Sim, M.D., Kyung Hee University Hospital at Gangdong

Study record dates

Study Major Dates

• Study Start: December 1, 2011
• Primary Completion (ACTUAL): August 1, 2012
• Study Completion (ACTUAL): October 1, 2012

Study Registration Dates

• First Submitted: April 24, 2012
• First Submitted That Met QC Criteria: March 27, 2019
• First Posted (ACTUAL): March 28, 2019

Study Record Updates

• Last Update Posted (ACTUAL): March 28, 2019
• Last Update Submitted That Met QC Criteria: March 27, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Keywords: Botulinum Toxin; Glabella line; Glabella lines
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Cholinergic Agents; Membrane Transport Modulators; Acetylcholine Release Inhibitors; Neuromuscular Agents; Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA
• Other Study ID Numbers: MT_PRT_GL02